Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 16

2348P - High-throughput screening reveals GSK1838705A as a potent inhibitor of CAFs-promoted tumor progression in esophageal squamous cell carcinoma

Date

21 Oct 2023

Session

Poster session 16

Topics

Cancer Biology;  Pathology/Molecular Biology;  Cancer Research

Tumour Site

Presenters

hongfang zhang

Citation

Annals of Oncology (2023) 34 (suppl_2): S1190-S1201. 10.1016/S0923-7534(23)01928-2

Authors

H. zhang1, J. yue1, H. jiang2, L. qiu1, K. zhang3, R. zhou4, B. Xia3, S. Ma3

Author affiliations

  • 1 Hangzhou Cancer Institution, Hangzhou Cancer Hospital, 310002 - Hangzhou/CN
  • 2 Department Of Cardiothoracic Surgery, Affiliated Hangzhou First People's Hospital, Zheijang University School of Medicine, 310006 - Hangzhou/CN
  • 3 Department Of Radiation Oncology, Hangzhou Cancer Hospital, 310002 - Hangzhou/CN
  • 4 Department Of Pathology, Hangzhou Cancer Hospital, 310002 - Hangzhou/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2348P

Background

Esophageal squamous cell carcinoma is a malignance with high invasiveness. Cancer-associated fibroblasts (CAFs) as one major component of tumor microenvironment (TME), promotes tumor initiation and progression. Our previous studies revealed that CAFs mediated ESCC cells significant resistance to a variety of chemotherapeutic drugs and ionizing irradiation. How to inhibit the tumor-promoting activity of CAFs is of critically important for the radical treatment of ESCC.

Methods

Using high-throughput screening, 157 inhibitors of cytokines/chemokines were tested for their effect on the cell viability of CAFs, matched normal fibroblasts (NFs), ESCC cells as well as normal esophageal epithelial cell Het-1A. We also investigated the effect of the inhibitors on cell cycle distribution, ROS accumulation and cell apoptosis of CAFs. The expressions of α-SMA, a marker of CAFs activation, was detected in CAFs treated with the inhibitors. By establishment of xenograft tumors in BALB/c mice, the effect of the inhibitors on CAFs-promoted ESCC growth was studied.

Results

By high-throughput screening, GSK1838705A, an inhibitor of IGF-1R kinase, was discovered as a potent inhibitor of CAFs activity in ESCC. Compared with NFs, ESCC cells as well as Het-1A, the viability of CAFs was significantly reduced when exposure to GSK1838705A. Furthermore, GSK1838705A arrested the cell cycle of CAFs in G2/M phase, promoted cell apoptosis and ROS accumulation. The expression of α-SMA was signifcantly reduced when CAFs were treated with GSK1838705A. In vivo studies demonstrated that GSK1838705A significantly repressed the tumor-promoting activity of CAFs. Immunohistochemical analysis showed that GSK1838705A significantly reduced the percentage of CAFs in xenograft tumor tissues.

Conclusions

GSK1838705A is a potent inhibitor of CAFs which promote ESCC progression. The combination of GSK1838705A and chemoradiotherapy may be a promising strategy against ESCC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.